Clinical Professor in Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.
Joined December 2019
- Tweets167
- Following239
- Followers238
- Likes117
Frede Donskov retweeted
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
Frede Donskov retweeted
Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effekt. Så hjælp @sophieloehde og sundheden, @JeppeBruus:
Sæt prisen højt op, så vi kan få en #røgfrifremtid
#dkpol #sundpol
altinget.dk/sundhed/artikel/… – at Copenhagen, Denmark
Frede Donskov retweeted
I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David McDermott is certainly none of the above and still made it! @Uromigos gbr01.safelinks.protection.o…
Frede Donskov retweeted
Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN+ST 232, ST alone 135). sciencedirect.com/science/ar… – at Vejprnice, Česká republika
Frede Donskov retweeted
The new Prime Minister of Italy.
Wow. xitter.cf/FuryOriental/status/15…
Frede Donskov retweeted
About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot
Frede Donskov retweeted
A waterfall plot or a tidal wave 🌊???? 🤩 😯
99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!!
#ESMO22 @myESMO @MyriamChalabi
Frede Donskov retweeted
#ESMO22 Presidential symposium - adjuvant nivo/ipi in #RCC by @motzermd:
- 15% pT2a g3/4, pT2b
- 5% sarcomatoid (pdl1 status pending)
- placebo arm 24-mos DFS rate 74% (note 67% in KN-564)
- 1 in 3 d/c due to drug tox
@DrChoueiri @montypal @neerajaiims @BradMcG04 @OncoAlert – at Paris, France
Frede Donskov retweeted
Our 30-month #KYN564 adjuvant RCC trial is published @TheLancetOncol —led by @tompowles1, presented #GU22 @ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant @OncoAlert
sciencedirect.com/science/ar…
Frede Donskov retweeted
Our @IMDConline paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is out in @ElsevierConnect Clinical Genitourinary Cancers..1/6🧵
clinical-genitourinary-cance…
Frede Donskov retweeted
CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC
@JournalCancer @OncoAlert @DrChoueiri
acsjournals.onlinelibrary.wi…
Frede Donskov retweeted
A very moving tribute to Dr. Christopher Wood, MD by Dr. Nizar Tannir, MD, FACP.
Check out kidney-cancer-journal.com/KC…
#KidneyCancer #RCC #RenalCancer @KidneyCancer #MedTwitter
Frede Donskov retweeted
It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021:
Some negative, some positive, some led to @FDAOncology approval; we learned from all!
Feel free to add & retweet & tag anyone involved
This is not an exhaustive list
@OncoAlert
Frede Donskov retweeted
High baseline Dual-layer CT derived iodine concentration associated with 4 times better treatment response and 3 times more favorable survival in patients with metastatic #kidneycancer @AJR_Radiology @AUHdk @AarhusUni
@OncoAlert @FDonskov @ICIS_News
High iodine concentration and high Zeffective are significant predictors of better treatment response and survival in metastatic renal cell carcinoma.
ajronline.org/doi/abs/10.221…
Frede Donskov retweeted
Thankful for...foundational science funded by @NIH and others, dedicated patient advocacy @VHLAlliance, translation of basic mechanism to intervention, the power of a small disease market to rally such a big development, @FDA approval, & VHL patients who have taught us so much.
Just in @NEJM 👉HIF-2α inhibitor Belzutifan 120 mg QD PO leads to 49% ORR in pts with #kidneycancer associated with VHL disease. Open acccess👉bit.ly/3l8Y48J Congrats @EJonasch & team Very proud to see @maughanonc @huntsmancancer @Huntsman_GU 👇 @OncoAlert @NeliMUlrich
Frede Donskov retweeted
1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in @NEJM ! A step towards better outcomes for all our patients with kidney cancer!
nejm.org/doi/full/10.1056/NE…
@OncoAlert @tompowles1
Frede Donskov retweeted
JUST IN: @US_FDA approves HIF-2 inhibitor Belzutifan in cancers linked to Von Hippel-Lindau Disease @VHLAlliance @kidneycan @KidneyCancer @OncoAlert --Study led by @EJonasch @MDAndersonNews and @theNCI group with #Srinivasan & presented @ASCO #ASCO21
onclive.com/view/fda-approve…
Frede Donskov retweeted
Just in: @US_FDA approved the combination of lenvatinib + pembrolizumab for first-line treatment of patients with advanced renal cell carcinoma (RCC). Approval based on CLEAR study published @NEJM @ASCO @OncoAlert
nejm.org/doi/full/10.1056/NE…
Frede Donskov retweeted
Great news!
Just in: @US_FDA Grants Priority Review to @Merck sBLA for pembrolizumab as Adjuvant Therapy in Patients With RCC post Surgery. Application Based on KEYNOTE-564 presented at #ASCO21; PDUFA date: Dec 10, 2021 @ASCO @OncoAlert @BusinessWire @DanaFarber_GU
businesswire.com/news/home/2…
